

FTO Antibody (NT)
Rabbit Polyclonal Antibody
Catalog # ABV11314**Specification**

FTO Antibody (NT) - Product Information

Application	WB, IHC, FC
Primary Accession	O9C0B1
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	58282

FTO Antibody (NT) - Additional Information**Gene ID** 79068

Positive Control	Western blot: NCI-H460 cell lysate, IHC: human brain tissue , FACS: NCI-H292 cells.
Application & Usage	Western blot: ~1:1000, IHC: ~1:50-1:100, FACS: ~1:10-1:50.

Other Names

FTO; KIAA1752; Alpha-ketoglutarate-dependent dioxygenase FTO; Fat mass and obesity-associated protein.

Target/Specificity

FTO

Antibody Form

Liquid

Appearance

Colorless liquid

Formulation

100 µl of antibody in PBS with 0.09% (W/V) sodium azide

Handling

The antibody solution should be gently mixed before use.

Reconstitution & Storage

-20 °C

Background Descriptions**Precautions**

FTO Antibody (NT) is for research use only and not for use in diagnostic or therapeutic procedures.

FTO Antibody (NT) - Protein Information

Name FTO {ECO:0000303|PubMed:17496892, ECO:0000312|HGNC:HGNC:24678}

Function

RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis (PubMed:22002720, PubMed:25452335, PubMed:26457839, PubMed:26458103, PubMed:28002401, PubMed:30197295). Specifically demethylates N(6)- methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes (PubMed:22002720, PubMed:25452335, PubMed:26457839, PubMed:26458103, PubMed:30197295). M6A demethylation by FTO affects mRNA expression and stability (PubMed:30197295). Also able to demethylate m6A in U6 small nuclear RNA (snRNA) (PubMed:30197295). Mediates demethylation of N(6),2'-O- dimethyladenosine cap (m6A(m)), by demethylating the N(6)-methyladenosine at the second transcribed position of mRNAs and U6 snRNA (PubMed:28002401, PubMed:30197295). Demethylation of m6A(m) in the 5'-cap by FTO affects mRNA stability by promoting susceptibility to decapping (PubMed:28002401). Also acts as a tRNA demethylase by removing N(1)-methyladenine from various tRNAs (PubMed:30197295). Has no activity towards 1-methylguanine (PubMed:20376003). Has no detectable activity towards double-stranded DNA (PubMed:20376003). Also able to repair alkylated DNA and RNA by oxidative demethylation: demethylates single-stranded RNA containing 3-methyluracil, single- stranded DNA containing 3-methylthymine and has low demethylase activity towards single-stranded DNA containing 1-methyladenine or 3-methylcytosine (PubMed:18775698, PubMed:20376003). Ability to repair alkylated DNA and RNA is however unsure in vivo (PubMed:18775698, PubMed:20376003). Involved in the regulation of fat mass, adipogenesis and body weight, thereby contributing to the regulation of body size and body fat accumulation (PubMed:18775698, PubMed:20376003). Involved in the regulation of thermogenesis and the control of adipocyte differentiation into brown or white fat cells (PubMed:26287746). Regulates activity of the dopaminergic midbrain circuitry via its ability to demethylate m6A in mRNAs (By similarity). Plays an oncogenic role in a number of acute myeloid leukemias by enhancing leukemic oncogene-mediated cell transformation: acts by mediating m6A demethylation of target transcripts such as MYC, CEBPA, ASB2 and RARA, leading to promote their expression (PubMed:28017614, PubMed:29249359).

Cellular Location

Nucleus. Nucleus speckle. Cytoplasm Note=Localizes mainly in the nucleus, where it is able to demethylate N(6)-methyladenosine (m6A) and N(6),2'-O-dimethyladenosine cap (m6A(m)) in U6 small nuclear RNA (snRNA), N(1)-methyladenine from tRNAs and internal m6A in mRNAs (PubMed:30197295). In the cytoplasm, mediates demethylation of m6A and m6A(m) in mRNAs and N(1)-methyladenine from tRNAs (PubMed:30197295).


Tissue Location

Ubiquitously expressed, with relatively high expression in adrenal glands and brain; especially in hypothalamus and pituitary (PubMed:17434869, PubMed:17496892). Highly expressed in highly expressed in acute myeloid leukemias (AML) with t(11;11)(q23;23) with KMT2A/MLL1 rearrangements, t(15;17)(q21;q21)/PML-RARA, FLT3-ITD, and/or NPM1 mutations (PubMed:28017614).


FTO Antibody (NT) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

FTO Antibody (NT) - Images

Formalin-fixed and paraffin-embedded human brain tissue reacted with FTO antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining.



FTO Antibody (NT) - Background

FTO (Fat mass-and obesity-associated gene) is the responsible gene for mouse 'fused toes' mutation. An association between FTO genotype and type 2 diabetes has been confirmed. The presence of the FTO rs9939609 A-allele was found to be positively correlated with other symptoms of the metabolic syndrome, including higher fasting insulin, glucose, triglycerides, and lower HDL-cholesterol.